Drug Profile
Research programme: gastrointestinal disorders therapy - Williamsburg Holdings
Alternative Names: AGI-025; Levosulpiride prodrugLatest Information Update: 29 Jul 2011
Price :
$50
*
At a glance
- Originator Williamsburg Holdings
- Developer AGI Therapeutics
- Class
- Mechanism of Action Dopamine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastrointestinal disorders